Neurology of Rheumatologic Disorders

Neurology of Systemic Disease (J Biller, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurology of Systemic Disease


Rheumatologic diseases encompass autoimmune and inflammatory disorders of the joints and soft tissues that often involve multiple organ systems, including the central and peripheral nervous systems. Common features include constitutional symptoms, arthralgia and arthritis, myalgia, and sicca symptoms. Neurological manifestations may present in patients with preexisting rheumatologic diagnoses, occur concurrently with systemic signs and symptoms, or precede systemic manifestations by months to years. Rheumatic disorders presenting as neurological syndromes may pose diagnostic challenges. Advances in immunosuppressive treatment of rheumatologic disease have expanded the treatment armamentarium. However, serious neurotoxic effects have been reported with both old and newer agents. Familiarity with neurological manifestations of rheumatologic diseases, diagnosis, and potential nervous system consequences of treatment is important for rapid diagnosis and appropriate intervention. This article briefly reviews the diverse neurological manifestations and key clinical features of rheumatic disorders and the potential neurological complications of agents commonly used for treatment.


Connective tissue disease Systemic lupus erythematosus Neuropsychiatric lupus Antiphospholipid antibody syndrome Rheumatoid arthritis Sjögren’s syndrome Vasculitis Giant cell arteritis Takayasu’s arteritis Immune complex vasculitis Antineutrophil-cytoplasmic-antibody-associated vasculitis Behçet’s disease Stroke Mononeuritis multiplex Neuropathy Cranial neuropathy Myelopathy Inflammatory myositis Dermatomyositis Polymyositis Inclusion body myositis Sarcoidosis Neurosarcoidosis IgG4-related disorders Neurotoxicity 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819–31.PubMedGoogle Scholar
  2. 2.••
    Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797–808. This article reviews new classification, nomenclature, and diagnostic criteria incorporating newer autoantibodies to facilitate an earlier and more specific diagnosis and treatment initiation for several common rheumatologic disorders.PubMedGoogle Scholar
  3. 3.
    Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23(5):S120.PubMedGoogle Scholar
  4. 4.
    Joseph FG, Lammie GA, Scolding NJ. CNS lupus A study of 41 patients. Neurology. 2007;69(7):644–54.PubMedGoogle Scholar
  5. 5.
    Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.Google Scholar
  6. 6.
    Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6(6):358–67.PubMedGoogle Scholar
  7. 7.
    Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology. 2002;41(6):619–30.PubMedGoogle Scholar
  8. 8.
    Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke. 1989;20(5):583–91.PubMedGoogle Scholar
  9. 9.
    Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52(9):2774–82.PubMedGoogle Scholar
  10. 10.
    Cervera R, Boffa MC, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18(10):889–93.PubMedGoogle Scholar
  11. 11.
    Hanly JG, Urowitz MB, O'Keeffe AG, Gordon C, Bae SC, Sanchez‐Guerrero J, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013;65(11):2887–97.PubMedGoogle Scholar
  12. 12.
    Sfikakis PP, Mitsikostas DD, Manoussakis MN, Foukaneli D, Moutsopoulos HM. Headache in systemic lupus erythematosus: a controlled study. Rheumatology. 1998;37(3):300–3.Google Scholar
  13. 13.
    Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63(10):1808–12.PubMedGoogle Scholar
  14. 14.
    Greenberg BM. The neurologic manifestations of systemic lupus erythematosus. Neurologist. 2009;15(3):115–21.PubMedGoogle Scholar
  15. 15.
    Toyota T, Akamatsu N, Tanaka A, Shouzaki T, Tsuji S, Saito K, et al. Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus. Epilepsia. 2013;54(3):e33–6.PubMedGoogle Scholar
  16. 16.
    Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology. 2002;41(6):605–18.PubMedGoogle Scholar
  17. 17.
    Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 2003;12(12):883–90.PubMedGoogle Scholar
  18. 18.
    Ferreira S, D'Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology. 2005;44(4):434–42.PubMedGoogle Scholar
  19. 19.
    Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59(2):120–4.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm. 2013;120(11):1579–89.PubMedGoogle Scholar
  21. 21.
    Erre GL, Bosincu L, Faedda R, Fenu P, Masala A, Sanna M, et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int. 2014;34(4):535–41.PubMedGoogle Scholar
  22. 22.
    Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev. 2011;11(2):123–31.PubMedGoogle Scholar
  23. 23.
    Blankenship LD, Basford JR, Strommen JA, Andersen RJ. Hypoglossal nerve palsy from cervical spine involvement in rheumatoid arthritis: 3 case reports. Arch Phys Med Rehabil. 2002;83(2):269–72.PubMedGoogle Scholar
  24. 24.
    Younger DS. Vasculitis of the nervous system. Curr Opin Neurol. 2004;17(3):317–36.PubMedGoogle Scholar
  25. 25.
    Ağildere AM, Tutar NU, Yücel E, Coşkun M, Benli S, Aydin P. Pachymeningitis and optic neuritis in rheumatoid arthritis: MRI findings. Br J Radiol. 1999;72(856):404–7.PubMedGoogle Scholar
  26. 26.
    Yücel AE, Kart H, Aydin P, Ağildere AM, Benli S, Altinörs N, et al. Pachymeningitis and optic neuritis in rheumatoid arthritis: successful treatment with cyclophosphamide. Clin Rheumatol. 2001;20(2):136–9.PubMedGoogle Scholar
  27. 27.
    Miró Ó, Pedrol E, Casademont J, García-Carrasco M, Sanmarti R, Cebrián M, et al. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum. 1996;25(6):421–8.PubMedGoogle Scholar
  28. 28.
    Kahlenberg JM. Neuromyelitis spectrum disorder as an initial presentation of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2011;40(4):343–8.PubMedGoogle Scholar
  29. 29.
    Delalande S, DeSeze J, Fauchais A, Hachulla E, Stojkovic T, et al. Neurologic manifestation in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280–91.Google Scholar
  30. 30.
    Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, et al. Peripheral neuropathy associated with primary Sjögren's syndrome. J Neurol Neurosurg Psychiatry. 1994;57(8):983–6.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Goransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjögren syndrome: a population-based study. Arch Neurol. 2006;63(11):1612–5.PubMedGoogle Scholar
  32. 32.
    Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjögren’s syndrome. Ann Rheum Dis. 2004;63:616–20.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Govoni M, Padovan M, Rizzo N, Trotta F. CNS involvement in primary Sjögren’s syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs. 2001;15:597–607.PubMedGoogle Scholar
  34. 34.
    Sharma R, Chilukuri V, Sarma AK, Gokhale S. Primary Sjogren’s syndrome presenting as acute cerebellitis. J Clin Neurosci. 2014;21(3):508–9.PubMedGoogle Scholar
  35. 35.
    Noseworthy JH, Bass BH, Vandervoort MK, et al. The prevalence of primary Sjögren’s syndrome in a multiple sclerosis population. Ann Neurol. 1989;25:95–8.PubMedGoogle Scholar
  36. 36.
    Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry. 2006;77:290–5.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Bourahoui A, De Seze J, Guttierez R, et al. CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol. 2004;11:525–9.PubMedGoogle Scholar
  38. 38.
    Tsai KY, Tsai CP, Liao N. Sjogren’s syndrome with central nervous system involvement presenting as multiple sclerosis with failure response to beta-interferon. Eur Neurol. 2001;45:59–60.PubMedGoogle Scholar
  39. 39.
    Auger RG. Role of the masseter reflex in the assessment of subacute sensory neuropathy. Muscle Nerve. 1998;21(6):800–1.PubMedGoogle Scholar
  40. 40.
    Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications. Muscle Nerve. 2003;28(5):553–60.PubMedGoogle Scholar
  41. 41.
    Murata Y, Maeda K, Kawai H, et al. Antiganglion neuron antibodies correlate with neuropathy in Sjögren's syndrome. Neuroreport. 2005;16(7):677–81.PubMedGoogle Scholar
  42. 42.
    Katz JS, Houroupian D, Ross MA. Multisystem neuronal involvement and sicca complex: broadening the spectrum of complications. Muscle Nerve. 1999;22(3):404–7.PubMedGoogle Scholar
  43. 43.
    Rafai MA, Boulaajaj FZ, Moutawakil F, Addali N, El Moutawakkil B, Fadel H, et al. Neurological manifestations revealing primitive Gougerote–Sjogren syndrome: 9 cases. Joint Bone Spine. 2009;76(2):139–45.PubMedGoogle Scholar
  44. 44.
    Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sjögren’s syndrome. Rev Neurol (Paris). 2002;158(10 Pt 1):959–65.Google Scholar
  45. 45.
    Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med. 1991;325:1487–98.PubMedGoogle Scholar
  46. 46.
    Sultan SM. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology. 2002;41:22–6.PubMedGoogle Scholar
  47. 47.
    Gordon RM, Silverstein A. Neurological manifestations in progressive systemic sclerosis. Arch Neurol. 1970;22(2):126.PubMedGoogle Scholar
  48. 48.
    Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol. 1992;49(12):1292–5.PubMedGoogle Scholar
  49. 49.
    Hietarinta M, Lassila O. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol. 1994;23(2):64.PubMedGoogle Scholar
  50. 50.
    Ranque B, Authier FJ. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci. 2007;1108:268–82.PubMedGoogle Scholar
  51. 51.
    Wise TN, Ginzler EM. Scleroderma cerebritis, an usual manifestation of progressive systemic sclerosis. Dis Nerv Syst. 1975;36(2):60–2.PubMedGoogle Scholar
  52. 52.
    Lindstrom KM, Cousar JB, Lopes MBS. IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol. 2010;120(6):765–76.PubMedGoogle Scholar
  53. 53.
    Ohyama K, Koike H, Iijima M, Hashimoto R, Tomita M, Kawagashira Y, et al. IgG4-related neuropathy: a case report. JAMA Neurol. 2013;70(4):502–5.PubMedGoogle Scholar
  54. 54.••
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. This is an updated comprehensive nomenclature and classification scheme for vasculitis in patients with rheumatologic conditions, other associated systemic disorders, and infectious diseases.PubMedGoogle Scholar
  55. 55.
    Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. Am J Neuroradiol. 1999;20(1):75–85.PubMedGoogle Scholar
  56. 56.•
    Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. 2011;10(6):561–72. This is a detailed overview of the clinical presentation and diagnostic challenges distinguishing primary angiitis of the CNS from vasculitis associated with other disorders.PubMedGoogle Scholar
  57. 57.
    Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain. 1999;122(11):2183–94.PubMedGoogle Scholar
  58. 58.
    Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.PubMedGoogle Scholar
  59. 59.
    Berrocal JG, Vargas JA, Vaquero M, y Cajal SR, Ramírez-Camacho RA. Cogan's syndrome: an oculo-audiovestibular disease. Postgrad Med J. 1999;75(883):262–4.PubMedCentralGoogle Scholar
  60. 60.•
    Greco A, Gallo A, Fusconi M, Magliulo G, Turchetta R, Marinelli C, et al. Cogan's syndrome: an autoimmune inner ear disease. Autoimmun Rev. 2013;12(3):396–400. This is a review of the current understanding regarding the pathophysiology of Cogan’s syndrome, the causes of Cogan’s syndrome, and strategies for treating Cogan’s syndrome.PubMedGoogle Scholar
  61. 61.
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–71.PubMedGoogle Scholar
  62. 62.
    Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201–4.PubMedGoogle Scholar
  63. 63.
    Mason JC. Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol. 2010;6(7):406–15.PubMedGoogle Scholar
  64. 64.
    Rosenberg MR, Parshley M, Gibson S, Wernick R. Central nervous system polyarteritis nodosa. West J Med. 1990;153(5):553–6.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry. 1998;65(1):10–22.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Gayraud M, Guillevin L, Le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long‐term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg‐Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44(3):666–75.PubMedGoogle Scholar
  67. 67.
    Takanashi JI, Shirai K, Sugawara Y, Okamoto Y, Obonai T, Terada H. Kawasaki disease complicated by mild encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci. 2012;315(1):167–9.PubMedGoogle Scholar
  68. 68.
    Dengler LD, Capparelli EV, Bastian JF, Bradley DJ, Glode MP, Santa S, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998;17(6):478–81.PubMedGoogle Scholar
  69. 69.
    Tizard EJ. Complications of Kawasaki disease. Curr Paediatr. 2005;15(1):62–8.Google Scholar
  70. 70.
    Watts RA, Dharmapalaiah C. ANCA-associated vasculitis. Ultrasound. 2011(2012).Google Scholar
  71. 71.
    Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512–23.PubMedGoogle Scholar
  72. 72.
    Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66(6):704–9.PubMedGoogle Scholar
  73. 73.
    Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. 1995;20(4):1010–36.PubMedGoogle Scholar
  74. 74.
    Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum. 1984;14(1):60.PubMedGoogle Scholar
  75. 75.
    Van der Meulen MF, Bronner IM, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61(3):316–21.PubMedGoogle Scholar
  76. 76.
    Callen JP. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis and inclusion body myositis. Rheum Dis Clin N Am. 1994;20(4):943–53.Google Scholar
  77. 77.
    Hochberg MC, Feldman D, et al. Adult onset polymyositis/dermatomyositis. An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986;15(3):168–78.PubMedGoogle Scholar
  78. 78.
    Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve. 1998;21(1):115–7.PubMedGoogle Scholar
  79. 79.
    Garlepp MJ, Laing B, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol. 1994;98(1):40–5.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol. 2014;175(3):349–58.PubMedGoogle Scholar
  81. 81.
    Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep. 2013;13(1):1–9.Google Scholar
  82. 82.
    Delaney P. Neurologic manifestation of sarcoidosis. Ann Intern Med. 1977;87(3):336–45.PubMedGoogle Scholar
  83. 83.
    Spencer TS, Campellone JV, Maldonado I, Huang N, Usmani Q, Reginato AJ. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum. 2005;34:649–61.PubMedGoogle Scholar
  84. 84.
    Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and neurological manifestations. Arch Neurol. 1985;42:909–17.PubMedGoogle Scholar
  85. 85.
    Kellinghaus C, Schilling M, Ludemann P. Neurosarcoidosis: clinical experience and diagnostic pitfalls. Eur Neurol. 2004;51:84–8.PubMedGoogle Scholar
  86. 86.
    Whelan MA, Stern J. Sarcoidosis presenting as a posterior fossa mass. Surg Neurol. 1981;15:455–7.PubMedGoogle Scholar
  87. 87.
    Oksanen V, Fyhrquist F, Somer H, Gronhagen-Riska C. Angiotensin converting enzyme in cerebrospinal fluid: a new assay. Neurology. 1985;35:1220–3.PubMedGoogle Scholar
  88. 88.
    Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124(1):186–95.PubMedGoogle Scholar
  89. 89.••
    Segal BM. Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol. 2013;26(3):307–13. This article reviews the epidemiology of, clinical presentation of, pathophysiology of, diagnostic approach for, and treatment strategies for sarcoidosis of the CNS.PubMedGoogle Scholar
  90. 90.
    Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore). 1990;69(5):261–76.Google Scholar
  91. 91.
    El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22(6):554–60.PubMedGoogle Scholar
  92. 92.
    Liu CC, Lin YC, Lo CP, Chang TP. Cauda equina syndrome and dural ectasia: rare manifestations in chronic ankylosing spondylitis. Br J Radiol. 2011;84(1002):e123–5.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Poncelet A. The neurologic complications of Paget's disease. J Bone Miner Res. 1999;14 Suppl 2:88–91.PubMedGoogle Scholar
  94. 94.
    Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009;10(8):816–24.PubMedGoogle Scholar
  95. 95.•
    Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043–51. This article reviews cases of PML associated with rheumatologic disorders reported to the FDA Adverse Event Reporting System database and discusses the role of biological agents as a cause.PubMedGoogle Scholar
  96. 96.
    Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–64.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761–5.PubMedGoogle Scholar
  98. 98.
    Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116–28.PubMedGoogle Scholar
  99. 99.
    Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120(7):985–7.PubMedGoogle Scholar
  100. 100.
    Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti–tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.PubMedGoogle Scholar
  101. 101.
    Sofat N, Malik O, Higgens CS. Neurological involvement in patients with rheumatic disease. QJM. 2006;99(2):69–79.PubMedGoogle Scholar
  102. 102.
    Caress JB, Cartwright MS, Donofrio PD, Peacock JE. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60(11):1822–4.PubMedGoogle Scholar
  103. 103.
    Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011;23(3):278–81.PubMedGoogle Scholar
  104. 104.
    Garlepp MI, Dawkins RL, Christiansen FT. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J (Clin Res Ed). 1983;286(6375):1442.Google Scholar
  105. 105.
    Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122(9):715–24.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Neurology, Maguire 2700 Building 105Loyola University Medical Center, Stritch School of MedicineMaywoodUSA
  2. 2.Department of NeurologyCleveland Clinic of FloridaWestonUSA

Personalised recommendations